Serum Bicarbonate as a Marker to Predict Mortality in Toxic Epidermal Necrolysis

Abstract

Background: Toxic epidermal necrolysis (TEN) is a rare life-threatening disorder characterized by extensive epidermal necrolysis. Its mortality which varies from 20% to 60% is related to risk factors such as age, extent of epidermal detachment, and base deficit. Objectives: The purpose of this study is to investigate the risk factors of mortality in our patients with TEN. Patients and methods: From the year 2000 to 2006, the patients with TEN admitted to the National Taiwan University Hospital Burn Center were studied retrospectively using chart review. Eleven potential risk factors including age, gender, underlying disease, malignancy, extent of epidermal detachment, tachycardia, serum urea, glucose, base deficit, leucopenia, and intravenous infusion of immunoglobulin (IVIG) were analyzed. Patients were grouped into survivors (n = 11) and nonsurvivors (n = 5) after intensive care treatment. Logistic regression was used in multivariate analysis for identifying important predictors of mortality. Results: The mean age of the patients with TEN was 58 years, while the mean total body surface area of epidermal necrolysis was 66.3%. The overall mortality rate was 31.3%. Among the potential risk factors, only serum bicarbonate <20 mmol/L was found to have significant association with mortality (P = .0128) in our patients with TEN. The odds of mortality in the patients with TEN having serum bicarbonate <20 mmol/L was 40 times higher than those without. Conclusion: This study has shown that serum bicarbonate <20 mmol/L is the most important risk factor of mortality in our patients with TEN and it may be used as a marker to predict hospital mortality.

Keywords

toxic epidermal necrolysis serum bicarbonate mortality prediction

Get full access to this article

View all access options for this article.

References

Levi N. , Bastuji-Garin S. , Mockenhaupt M. , et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009; 123(2):e297-e304.

Roujeau JC , Kelly JP , Naldi L. , et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-1607.

Roujeau JC , Guillaume JC , Fabre JP , Penso D. , Fléchet ML , Girre JP Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990; 126(1):37-42.

Trent JT , Kirsner RS , Romanelli P. , Kerdel FA Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol. 2004;140(7): 890-892.

Ducic I. , Shalom A. , Rising W. , Nagamoto K. , Munster AM Outcome of patients with toxic epidermal necrolysis syndrome revisited . Plast Reconstr Surg. 2002;110(3):768-773.

Kim KJ , Lee DP , Suh HS , et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol. 2005;85(6):497-502.

Lebargy F. , Wolkenstein P. , Gisselbretcht M. , et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23(12):1237-1244.

Bastuji-Garin S. , Fouchard N. , Bertocchi M. , Roujeau JC , Revuz J. , Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000 ;115(2):149-153.

Imahara SD , Holmes JH , Heimbach DM , et al. SCORTEN overestimates mortality in the setting of standardized treatment protocol. J Burn Care Res. 2006;27(3):270-275.

10.

Creamer GL , Civil I. , Koelmeyer T. , Adams D. , Cacala S. , Thompson J. Population-based study of age, gender and causes of severe injury in Auckland, 2004. ANZ J Surg. 2008;78(11): 995-998.

11.

Prins C. , Kerdel FA , Padilla RS , et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases . Arch Dermatol. 2003;139(1):26-32.

12.

Rutherford EJ , Morris JA Jr , Reed GW , Hall KS Base deficit stratifies mortality and determines therapy. J Trauma. 1992; 33(3):417.

13.

Davis JW , Shackford SR , Holbrook TL Base deficit as a sensitive indicator of compensated shock and tissue oxygen utilization. Surg Gynecol Obstet. 1991 ;173(6):473-476.

14.

Davis JW , Kaups KL Base deficit in the elderly: a marker of severe injury and death. J Trauma. 1998;45(5):873-877.

15.

French LE , Trent JT , Kerdel FA Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol . 2006;6(4):543-549.

16.

Stella M. , Clemente A. , Bollero D. , Risso D. , Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach . A retrospective analysis. Burns. 2007;33(4):452-459.

17.

Bachot N. , Revuz J. , Roujeau JC Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33-36.

18.

Shortt R. , Gomez M. , Mittman N. , Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis . J Burn Care Rehabil. 2004;25(3):246-255.

19.

Arevalo JM , Lorente JA Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil. 1999;20(5):406-410.

20.

Bradley T. , Brown RE , Kucan JO , Smoot EC 3rd , Hussmann J. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg. 1995; 35(2):124-132.